Skip to main content

Advertisement

Table 1 Characteristics of evaluated groups

From: Influence of type 2 diabetes on symbolic analysis and complexity of heart rate variability in men

Characteristics T2D CG P-value
Age (years) 50.53 ± 6.96 50.26 ± 7.96 0.345
Body mass (Kg) 86.64 ± 13.86 80.24 ± 9.38 0.057
Height (m) 1.74 ± 0.09 1.75 ± 0.08 0.823
BMI (Kg/m2) 28.26 ± 4.13 26.21 ± 1.77 0.062
Percentage of total body fat 24.94 ± 6.20 23.38 ± 3.61 0.384
VO2 peak (ml/min) 1672.05 ± 345.01 1850.89 ± 238.09 0.070
Time of diabetes (years) 11.13 ± 6.41 - -
Laboratory Exams    
PCR (mg/dL) 1.12 ± 1.48 0.69 ± 0.66 0.874
HbA1c (%) 8.54 ± 2.15 5.85 ± 0.30 <0.001*
HbA1c (mmol/mol) 69.80 ± 23.55 40.44 ± 3.26 <0.001*
Estimated mean glycemia (mg/dL) 197.79 ± 61.91 119.47 ± 9.95 <0.001*
Total cholesterol (mg/dL) 193.79 ± 28.61 198.21 ± 39.33 0.635
HDL-cholesterol (mg/dL) 45.37 ± 10.32 46.79 ± 11.02 0.573
LDL-cholesterol (mg/dL) 113.53 ± 32.12 119.26 ± 30.62 0.253
VLDL-cholesterol (mg/dL) 33.84 ± 18.49 31.05 ± 16.11 0.452
Triglycerides (mg/dL) 170.47 ± 92.57 156.37 ± 80.06 0.093
Risk factors    
Hypertension 2 (10.53%) - -
Obesity 5 (26.31%) - -
Dyslipidemia 7 (36.84%) 9 (47.37%) -
Medications    
Oral hypoglycemic drugs 8 (42.11%) - -
Insulin 4 (21.05%) - -
Oral hypoglycemic drugs + insulin 4 (21.05%)   
Anti-hypertensive drugs 5 (26.31%) - -
ACE Inhibitor 1 (5.26%) - -
- Calcium channel blocker (amlodipina) 1 (5.26%) - -
- Angiotensin II receptor antagonist 2 (10.53%) - -
- Hydrochlorothiazide 1 (5.26%) - -
- Clonidine 1 (5.26%) - -
- Hypolipidemic drug 2 (10.53%) 3 (15.79%)  
Deep breathing testing    
E/I 1.27 ± 0.20 1.29 ± 0.16 0.352
ΔIE 18.53 ± 14.94 16.73 ± 8.82 0.494
  1. The data are presented in mean ± standard deviation. T2D = group with type 2 diabetes; CG = Control Group; BMI = body mass index; VO2 peak = oxygen consumption at peak of physical effort; PCR = C-reactive protein; HbA1c = glycated hemoglobin.*p < 0.05.